Intralymphatic Immunotherapy in Increasing Doses, After Subcutaneous Immunotherapy

NCT02679105 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Rhinitis, Allergic

Interventions

DRUG: ALK Alutard birch or 5-grasses
DRUG: ALK diluent

Sponsor

Karolinska Institutet

Collaborators

[object Object]
[object Object]
[object Object]